Important classifiers in the pathological evaluation of breast cancer, one of the most frequent of all human tumor types, are immunohistological parameters: HER2 status and the expression of estrogen and progesterone receptors are routinely used to determine breast cancer subtype and to guide optimal treatment plans accordingly [53–55]. This evidence concerns the gene ERBB2 and breast cancer.